Opioid receptor antagonist promotes angiogenesis in bile duct ligated rats. 2009

Negar Faramarzi, and Ata Abbasi, and Seyed M Tavangar, and Marjan Mazouchi, and Ahmad R Dehpour
Department of Pharmacology, Tehran University of Medical Sciences, Tehran, Iran.

OBJECTIVE Angiogenesis, formation of new capillaries from existing vasculature, plays a pivotal role in different pathological states such as many chronic inflammatory diseases including the chronic liver diseases. There is increasing evidence demonstrating accumulation of endogenous opioids and their role in the pathophysiology and manifestations of cholestasis, the main feature of a number of chronic progressive liver diseases. Hence, we investigated the significance of endogenous opioids in angiogenesis in an experimental model of cholestasis. METHODS Cholestasis was induced in male Sprague-Dawley rats by bile duct ligation and resection. Naltrexone, an opioid antagonist (20 mg/kg/day) was administered to cholestatic animals for 22 +/- 1 days. The serial sections from liver tissue were stained with von Willebrand Factor antibody and micro-vessel density was assessed by calculating mean micro-vessel number in three hot spots high power microscopic fields. RESULTS Naltrexone treatment in bile duct ligated rats led to a marked increase in the micro-vessel number (6.34 +/- 0.21 vs 5.61 +/- 0.22) (P < 0.05), which had already increased during cholestasis. CONCLUSIONS In order to clarify the impacts of opioid system blockade in cirrhosis, our findings demonstrate the promoting role of opioid antagonist in angiogenesis in a rat model of cholestasis.

UI MeSH Term Description Entries
D008026 Ligation Application of a ligature to tie a vessel or strangulate a part. Ligature,Ligations,Ligatures
D008297 Male Males
D009271 Naltrexone Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. Antaxone,Celupan,EN-1639A,Nalorex,Naltrexone Hydrochloride,Nemexin,ReVia,Trexan,EN 1639A,EN1639A
D009292 Narcotic Antagonists Agents inhibiting the effect of narcotics on the central nervous system. Competitive Opioid Antagonist,Narcotic Antagonist,Opioid Antagonist,Opioid Antagonists,Opioid Receptor Antagonist,Opioid Reversal Agent,Competitive Opioid Antagonists,Opioid Receptor Antagonists,Opioid Reversal Agents,Agent, Opioid Reversal,Agents, Opioid Reversal,Antagonist, Competitive Opioid,Antagonist, Narcotic,Antagonist, Opioid,Antagonist, Opioid Receptor,Antagonists, Competitive Opioid,Antagonists, Narcotic,Antagonists, Opioid,Antagonists, Opioid Receptor,Opioid Antagonist, Competitive,Opioid Antagonists, Competitive,Receptor Antagonist, Opioid,Receptor Antagonists, Opioid,Reversal Agent, Opioid,Reversal Agents, Opioid
D011957 Receptors, Opioid Cell membrane proteins that bind opioids and trigger intracellular changes which influence the behavior of cells. The endogenous ligands for opioid receptors in mammals include three families of peptides, the enkephalins, endorphins, and dynorphins. The receptor classes include mu, delta, and kappa receptors. Sigma receptors bind several psychoactive substances, including certain opioids, but their endogenous ligands are not known. Endorphin Receptors,Enkephalin Receptors,Narcotic Receptors,Opioid Receptors,Receptors, Endorphin,Receptors, Enkephalin,Receptors, Narcotic,Receptors, Opiate,Endorphin Receptor,Enkephalin Receptor,Normorphine Receptors,Opiate Receptor,Opiate Receptors,Opioid Receptor,Receptors, Normorphine,Receptors, beta-Endorphin,beta-Endorphin Receptor,Receptor, Endorphin,Receptor, Enkephalin,Receptor, Opiate,Receptor, Opioid,Receptor, beta-Endorphin,Receptors, beta Endorphin,beta Endorphin Receptor,beta-Endorphin Receptors
D003135 Common Bile Duct The largest bile duct. It is formed by the junction of the CYSTIC DUCT and the COMMON HEPATIC DUCT. Choledochus,Bile Duct, Common,Common Bile Ducts,Duct, Common Bile
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001651 Cholestasis, Extrahepatic Impairment of bile flow in the large BILE DUCTS by mechanical obstruction or stricture due to benign or malignant processes. Bile Duct Obstruction, Extrahepatic,Biliary Stasis, Extrahepatic,Extrahepatic Cholestasis,Extrahepatic Biliary Stasis
D017207 Rats, Sprague-Dawley A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company. Holtzman Rat,Rats, Holtzman,Sprague-Dawley Rat,Rats, Sprague Dawley,Holtzman Rats,Rat, Holtzman,Rat, Sprague-Dawley,Sprague Dawley Rat,Sprague Dawley Rats,Sprague-Dawley Rats

Related Publications

Negar Faramarzi, and Ata Abbasi, and Seyed M Tavangar, and Marjan Mazouchi, and Ahmad R Dehpour
November 2006, Gut,
Negar Faramarzi, and Ata Abbasi, and Seyed M Tavangar, and Marjan Mazouchi, and Ahmad R Dehpour
January 1984, Biological research in pregnancy and perinatology,
Negar Faramarzi, and Ata Abbasi, and Seyed M Tavangar, and Marjan Mazouchi, and Ahmad R Dehpour
February 1992, The American journal of physiology,
Negar Faramarzi, and Ata Abbasi, and Seyed M Tavangar, and Marjan Mazouchi, and Ahmad R Dehpour
January 2003, Journal of gastroenterology,
Negar Faramarzi, and Ata Abbasi, and Seyed M Tavangar, and Marjan Mazouchi, and Ahmad R Dehpour
January 1993, Archives internationales de physiologie, de biochimie et de biophysique,
Negar Faramarzi, and Ata Abbasi, and Seyed M Tavangar, and Marjan Mazouchi, and Ahmad R Dehpour
June 1983, Clinical immunology and immunopathology,
Negar Faramarzi, and Ata Abbasi, and Seyed M Tavangar, and Marjan Mazouchi, and Ahmad R Dehpour
May 2006, Pathophysiology : the official journal of the International Society for Pathophysiology,
Negar Faramarzi, and Ata Abbasi, and Seyed M Tavangar, and Marjan Mazouchi, and Ahmad R Dehpour
July 2000, Journal of hepatology,
Negar Faramarzi, and Ata Abbasi, and Seyed M Tavangar, and Marjan Mazouchi, and Ahmad R Dehpour
April 1991, Journal of chemotherapy (Florence, Italy),
Negar Faramarzi, and Ata Abbasi, and Seyed M Tavangar, and Marjan Mazouchi, and Ahmad R Dehpour
January 2001, Annals of nutrition & metabolism,
Copied contents to your clipboard!